Inmagene's OX40 mAb, with an extended half-life and silenced ADCC, enters POC study in Atopic Dermatitis
Article Date
August 15, 2023
This article is featured on another website.
Go to article
August 17, 2023
Chime Biologics Relisted in the Hurun Future Unicorns in the World 2023, Recognized by the Market for Growth
August 17, 2023
Chime Biologics Relisted in the Hurun Future Unicorns in the World 2023, Recognized by the Market for Growth
June 27, 2023
Windtree Therapeutics Appoints Mark Strobeck, Ph.D. to Board of Directors
WARRINGTON, Pa. , June 27, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today announced that the Company appointed Mark Strobeck , Ph.D.
June 27, 2023
Windtree Therapeutics Appoints Mark Strobeck, Ph.D. to Board of Directors
WARRINGTON, Pa. , June 27, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today announced that the Company appointed Mark Strobeck , Ph.D.